enGene Holdings Inc. Common Stock

NasdaqCM ENGN

enGene Holdings Inc. Common Stock Price to Sales Ratio (P/S) on February 05, 2025

enGene Holdings Inc. Common Stock Price to Sales Ratio (P/S) is NA on February 05, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • enGene Holdings Inc. Common Stock 52-week high Price to Sales Ratio (P/S) is NA on February 05, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • enGene Holdings Inc. Common Stock 52-week low Price to Sales Ratio (P/S) is NA on February 05, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • enGene Holdings Inc. Common Stock average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
SV Wall Street
NasdaqCM: ENGN

enGene Holdings Inc. Common Stock

CEO Mr. Ronald H. W. Cooper
IPO Date Feb. 1, 2022
Location Canada
Headquarters 7171 Rue Frederick Banting
Employees 31
Sector Healthcare
Industries
Biotechnology
Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

StockViz Staff

February 6, 2025

Any question? Send us an email